Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help
Search by PDB author
4JVH
DownloadVisualize
BU of 4jvh by Molmil
Structure of the star domain of quaking protein in complex with RNA
Descriptor: Protein quaking, RNA (5'-R(*UP*UP*CP*AP*CP*UP*AP*AP*CP*AP*A)-3'), SULFATE ION
Authors:Teplova, M, Hafner, M, Teplov, D, Essig, K, Tuschl, T, Patel, D.J.
Deposit date:2013-03-25
Release date:2013-05-08
Method:X-RAY DIFFRACTION (3.501 Å)
Cite:Structure-function studies of STAR family Quaking proteins bound to their in vivo RNA target sites.
Genes Dev., 27, 2013
4JVY
DownloadVisualize
BU of 4jvy by Molmil
Structure of the STAR (signal transduction and activation of RNA) domain of GLD-1 bound to RNA
Descriptor: Female germline-specific tumor suppressor gld-1, RNA (5'-R(P*CP*UP*AP*AP*CP*AP*A)-3')
Authors:Teplova, M, Hafner, M, Teplov, D, Essig, K, Tuschl, T, Patel, D.J.
Deposit date:2013-03-26
Release date:2013-05-08
Last modified:2017-11-15
Method:X-RAY DIFFRACTION (2.853 Å)
Cite:Structure-function studies of STAR family Quaking proteins bound to their in vivo RNA target sites.
Genes Dev., 27, 2013
7TYP
DownloadVisualize
BU of 7typ by Molmil
TEAD2 bound to GNE-7883
Descriptor: (8S)-5-(4-cyclohexylphenyl)-3-[3-(fluoromethyl)azetidine-1-carbonyl]-2-(3-methylpyrazin-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, Transcriptional enhancer factor TEF-4
Authors:Noland, C.L, Fong, R.
Deposit date:2022-02-14
Release date:2023-05-03
Last modified:2023-10-25
Method:X-RAY DIFFRACTION (1.6 Å)
Cite:Novel mechanism of YAP-TEAD inhibition results in targeted chromatin remodeling and reveals an expanded Hippo dependent landscape in cancers
To Be Published
7TYU
DownloadVisualize
BU of 7tyu by Molmil
TEAD2 bound to Compound 2
Descriptor: (3R)-1-[(8S)-5-(4-cyclohexylphenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonyl]pyrrolidine-3-carbonitrile, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, Transcriptional enhancer factor TEF-4
Authors:Noland, C.L, Fong, R.
Deposit date:2022-02-14
Release date:2023-05-03
Last modified:2023-10-25
Method:X-RAY DIFFRACTION (1.78 Å)
Cite:Novel mechanism of YAP-TEAD inhibition results in targeted chromatin remodeling and reveals an expanded Hippo dependent landscape in cancers
To Be Published
7TYQ
DownloadVisualize
BU of 7tyq by Molmil
TEAD2 bound to Compound 1
Descriptor: Transcriptional enhancer factor TEF-4, ethyl (8S)-7-oxo-5-[4-(trifluoromethyl)phenyl]-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate
Authors:Noland, C.L, Fong, R.
Deposit date:2022-02-14
Release date:2023-05-03
Last modified:2023-10-25
Method:X-RAY DIFFRACTION (1.88 Å)
Cite:Novel mechanism of YAP-TEAD inhibition results in targeted chromatin remodeling and reveals an expanded Hippo dependent landscape in cancers
To Be Published
6OQI
DownloadVisualize
BU of 6oqi by Molmil
CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine)
Descriptor: 5-fluoro-N-[5-(4-methylpiperazin-1-yl)pyridin-2-yl]-4-[(4S)-4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl]pyrimidin-2-amine, Cyclin-dependent kinase 2
Authors:Murray, J.M.
Deposit date:2019-04-26
Release date:2020-07-29
Last modified:2023-10-11
Method:X-RAY DIFFRACTION (2 Å)
Cite:Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bioorg.Med.Chem.Lett., 29, 2019
6OQL
DownloadVisualize
BU of 6oql by Molmil
CDK6 in complex with Cpd13 (R)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine
Descriptor: 5-fluoro-N-[5-(4-methylpiperazin-1-yl)pyridin-2-yl]-4-[(4R)-4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl]pyrimidin-2-amine, Cyclin-dependent kinase 6
Authors:Murray, J.M.
Deposit date:2019-04-26
Release date:2020-07-29
Last modified:2023-10-11
Method:X-RAY DIFFRACTION (2.707 Å)
Cite:Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bioorg.Med.Chem.Lett., 29, 2019
6OQO
DownloadVisualize
BU of 6oqo by Molmil
CDK6 in complex with Cpd24 N-(5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)pyrimidin-2-amine
Descriptor: Cyclin-dependent kinase 6, N-[5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl]-5-fluoro-4-[(4R)-4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl]pyrimidin-2-amine
Authors:Murray, J.M, Boenig, G.D.L.
Deposit date:2019-04-26
Release date:2020-07-29
Last modified:2021-08-11
Method:X-RAY DIFFRACTION (1.977 Å)
Cite:Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bioorg.Med.Chem.Lett., 29, 2019
4EOW
DownloadVisualize
BU of 4eow by Molmil
Crystal structure of a disease-associated anti-human GM-CSF autoantibody MB007
Descriptor: MB007 IgG1 Fab fragment light chain, MB007 human IgG1 Fab fragment heavy chain
Authors:Blech, M.
Deposit date:2012-04-16
Release date:2012-08-22
Last modified:2024-03-06
Method:X-RAY DIFFRACTION (1.97 Å)
Cite:Molecular structure of human GM-CSF in complex with a disease-associated anti-human GM-CSF autoantibody and its potential biological implications.
Biochem.J., 447, 2012
4G6J
DownloadVisualize
BU of 4g6j by Molmil
Crystal structure of human IL-1beta in complex with the therapeutic antibody binding fragment of canakinumab
Descriptor: Interleukin-1 beta, heavy chain of antibody binding fragment of canakinumab, light chain of antibody binding fragment of canakinumab
Authors:Blech, M, Hoerer, S.
Deposit date:2012-07-19
Release date:2012-12-19
Last modified:2023-09-13
Method:X-RAY DIFFRACTION (2.03 Å)
Cite:One traget-two different binding modes: Structural insights into gevokizumab and canakinumab interactions to interleukin-1beta
J.Mol.Biol., 425, 2013
4G5Z
DownloadVisualize
BU of 4g5z by Molmil
Crystal structure of the therapeutical antibody fragment of canakinumab in its unbound state
Descriptor: canakinumab antibody fragment heavy chain, canakinumab antibody fragment light chain
Authors:Blech, M, Hoerer, S.
Deposit date:2012-07-18
Release date:2012-12-19
Last modified:2023-09-13
Method:X-RAY DIFFRACTION (1.83 Å)
Cite:One target-two different binding modes: Structural insights into gevokizumab and canakinumab interactions to interleukin-1beta
J.Mol.Biol., 425, 2013
4G6M
DownloadVisualize
BU of 4g6m by Molmil
Crystal structure of human IL-1beta in complex with therapeutic antibody binding fragment of gevokizumab
Descriptor: Interleukin-1 beta, heavy chain of gevokizumab antibody binding fragment, light chain of gevokizumab antibody binding fragment
Authors:Blech, M, Hoerer, S.
Deposit date:2012-07-19
Release date:2012-12-19
Last modified:2023-09-13
Method:X-RAY DIFFRACTION (1.81 Å)
Cite:Crystal structure of human IL-1beta in complex with therapeutic antibody binding fragment of gevokizumab
J.Mol.Biol., 425, 2013
4G6K
DownloadVisualize
BU of 4g6k by Molmil
Crystal structure of the therapeutic antibody binding fragment of gevokizumab in its unbound state
Descriptor: heavy chain of gevokizumab antibody binding fragment, light chain of gevokizumab antibody binding fragment
Authors:Blech, M, Hoerer, S.
Deposit date:2012-07-19
Release date:2012-12-19
Last modified:2023-09-13
Method:X-RAY DIFFRACTION (1.9 Å)
Cite:One target-two different binding modes: Structural insights into gevokizumab and canakinumab interactions to interleukin-1beta
J.Mol.Biol., 425, 2013

218853

PDB entries from 2024-04-24

PDB statisticsPDBj update infoContact PDBjnumon